Explore treatment pathways from non-muscle-invasive to metastatic urothelial carcinoma.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Cancer confined to the bladder lining, often recurrent
Standard: TURBT + intravesical BCG or chemotherapy
Cancer has grown into the bladder muscle wall
Standard: Neoadjuvant chemotherapy + radical cystectomy or trimodal therapy
Advanced or metastatic urothelial carcinoma
Standard: Platinum-based chemotherapy or immunotherapy (if platinum-ineligible)
After progression on platinum chemotherapy
Standard: Immunotherapy (Pembrolizumab, Atezolizumab) or Enfortumab vedotin
Found in ~15-20% of metastatic urothelial cancers. FGFR inhibitors (Erdafitinib) target these alterations. Several FGFR-targeted trials are active.
PD-L1 expression helps predict immunotherapy response. Higher levels may indicate better response to checkpoint inhibitors like Pembrolizumab and Atezolizumab.
Highly expressed on urothelial cancer cells. Antibody-drug conjugate Enfortumab vedotin targets Nectin-4 and is now standard in 2nd-line treatment.
Microsatellite instability-high tumours (~2-5% of bladder cancers) respond well to immunotherapy. Testing identifies patients who may benefit from checkpoint inhibitors.
Loading trials from ClinicalTrials.gov...
Antibody-drug conjugates (Enfortumab vedotin, Sacituzumab govitecan), FGFR-targeted therapies, novel immunotherapy combinations, and bispecific antibodies are all in active trials for bladder cancer in the UK.
Yes. Immune checkpoint inhibitors (Pembrolizumab, Atezolizumab, Nivolumab, Avelumab) are approved for bladder cancer and many new immunotherapy combinations are in clinical trials.
Yes. For patients whose non-muscle invasive bladder cancer no longer responds to BCG, trials explore intravesical gene therapy, immunotherapy, and novel agents as alternatives to bladder removal.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.